PANDEMONIUM  DOCUMENT
      NEW  AFRICAN
                      DECEMBER 2000

ZAMBIA: COVER STORY

 A rash of complaints ...the tragic side-effects of
 Aids drugs


 Tragic underestimation of flesh-sloughing side-effects and failures in patient
 monitoring led to the deaths which forced South Africa to halt the clinical trials of
 the anti-Aids drug, Nevirapine, in April this year.

 A ghastly side-effect called Stephens-Johnson Syndrome (SJS) first start as a rash
 but kills patients after eating up their flesh in serious cases.

 Official data available before the clinical trials commenced showed that Nevirapine
 was five times more likely to cause the deadly, drug-induced SJS than was the more
 expensive AZT, which equally has deadly toxic side-effects.

 SJS killed two of the five women in the South African trials, appearing within weeks
 of commencing Nevirapine — at first as a rash (but all the skin can be sloughed off),
 mouth and trachea blisters, and lungs and intestines can shed layers inside the body.

 Prevention of side-effects requires careful patient monitoring. By far the most
 common complication is described as “rash” when mild, or as SJS when severe.
 Immediate withdrawal of Nevirapine is mandated in all but mild reactions.

 On 6 April this year, the PAC chief whip in South Africa, Patricia de Lille, said that
 she had uncovered a “nest of abuse and exploitation” in clinical trials of anti-Aids
 drugs in the country.

 Participants in the trials told De Lille of severe side effects and irregularities in the
 way patients were asked to sign consent forms they did not understand.

 In an interview with The Natal Witness, De Lille said: “One patient developed a rash
 all over the body and still has marks on the face. He told [the doctor in charge of the
 trials at the Kalafong Hospital in Pretoria] that this had happened since using the
 drugs, but the doctor said it was not the drugs causing the rash, but the HIV virus”.

 The Natal Witness also quoted De Lille saying that one woman went completely
 blind for two weeks, but regained her eyesight after discontinuing the drugs.

 Before De Lille’s remarks were even reported, the South African health minister,
 Manto Tshabalala-Msimang (who is a medical doctor herself) announced a halt to
 the Nevirapine trials. She told parliament that two of the five women died of liver
 damage, and there was a “probable” causal association with Nevirapine in the other
 three cases.

 But Kevin McKenna, a spokesman for the Nevirapine manufacturers, Boehringer
 Ingelheim, was not about to own up. “My information is that the actual link to
 Nevirapine is inconclusive, and that the company involved is examining the [deaths]
 and establishing the reasons”, he said at the time.

 But Boehringer itself had said on a New Zealand government website that:

 “The major clinical toxicity of Viramune [another name for Nevirapine] is rash,
 occurring in 16% of patients; [in one study as much as] 35% of patients experienced
 rash...

 “Severe or life-threatening rash occurred in 6.6% of Viramune-treated patients...
 Severe or life-threatening skin reactions have occurred in patients treated with
 Virumune, including SJS and TEN (toxic epidermal necrolysis). Fatal cases of SJS,
 TEN and hypersensitivity reactions have [also] been reported.

 “Severe and life-threatening hepatotoxicity, including fatal fulminant hepatitis, has
 occurred in patients treated with Viramune. Some of these cases began in the first
 few weeks of therapy. Monitoring of liver function tests is strongly recommended
 especially during the first six months of Viramune treatment.”

 But what Boehringer does not say is that the “hepatotoxicity” arises partly because
 the liver is the organ that must metabolise Nevirapine. Deaths from liver failure are
 not unheard of in such clinical trials, but are certainly minimised by proper
 monitoring.

 So, two of the five deaths that occurred in the Nevirapine trials in South Africa can
 be accounted for by “hepatotoxicity” as the health minister indicated in parliament.
 But what about the three other deaths described as “inconclusive” by the Boehringer
 spokesman?

 More than a rash

 Describing the side-effects of Nevirapine as a “rash” is misleading. Because the
 “rash” is neither cutaneous nor arising from localised causes, but systematically
 driven; and means the body is signalling a very serious illness. In the severe forms of
 Nevirapine effect, the reaction progresses in ways that depart from any known
 “rash”.

 A Carte Blanche TV documentary shown in South Africa recently said one patient,
 Rebecca, “went completely blind for two weeks.”

 Q: “What happened to your sight after you took the pills?”

 Rebecca: “I started to change. Blind... not hear[ing] nicely... not speak[ing]
 properly.”

 Rebecca also said she witnessed other symptoms, including anal bleeding, sores that
 would not heal, abdominal pains, weight loss, fevers and pneumonia. These could all
 be typical Aids symptoms, but Rebecca remains convinced it was the drug, not the
 virus.

 But these were no Aids symptoms. The rashes and sores observed were classic
 Nevirapne rash. The anal bleeding and abdominal pains bore testimony to
 Nevirapine’s predilection for affecting the gastrointestinal system as seen in the
 comparable clinical trial which ushered in the US Food and Drug Administration
 (FDA) approval of the drug on 24 June 1996.

 The full blindness was untreated SJS ocular sloughing. The blindness which,
 tellingly, healed on stopping medication was a reversal of SJS.

 These concerns are taken seriously in the European Union. On 12 April this year,
 the European Agency for the Evaluation of Medecines decided to maintain
 Nevirapine in its “under exceptional circumstances” category.

 Based on “continuing reports on incidents of these very severe reactions in
 1999/2000”, the European Agency issued an “urgent safety restriction” on
 Nevirapine to include new warnings on “life-threatening cutaneous and hepatic
 reactions”.

 In America, patients are advised to “dial 911 or rush to the nearest ER” on suspicion
 of an SJS reaction.

 A prudent person would ask whether medication requiring this level of support
 services is in any way appropriate for Africa.

 Against this backdrop, it is worrying that the Carte Blanche investigation reported
 problems with access to the medical files of the patients involved:

 Nelly: “They say the file is missing.”

 Carte Blanche: “The hospital registry told Nelly that her files were removed from
 the registry.”

 Case closed?

 Fintan Dunne

 Editor (Aidsmyth.com)
 
 

 Copyright © IC Publications Limited 2000. All rights reserved. No part of this site may be reproduced or
 transmitted in any form by any means or used for any business purpose without the written consent of the
 publisher. Whilst every effort has been made to ensure that the information contained herein is as accurate
 as possible, the publisher cannot accept responsibility for any consequences arising from its use.

http://www.africasia.com/icpubs/
 
 



 

NEXT

BACK TO GEOCITIES

BACK TO PANDEMONIUM

TO STEVE'S PAGE

TO REVELATIONS